ImmunoPrecise Antibodies (IPA) Set to Announce Earnings on Monday

Posted by Ethan Ryder on Sep 14th, 2024

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) is scheduled to announce its earnings results before the market opens on Monday, September 16th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) last posted its earnings results on Monday, July 29th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). The company had revenue of $4.76 million during the quarter, compared to the consensus estimate of $4.92 million. ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunoPrecise Antibodies Price Performance

ImmunoPrecise Antibodies stock opened at $0.67 on Friday. The stock has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $1.12. ImmunoPrecise Antibodies has a 12 month low of $0.58 and a 12 month high of $2.60. The company has a market capitalization of $18.29 million, a PE ratio of -1.63 and a beta of 0.10. The company has a current ratio of 1.41, a quick ratio of 1.15 and a debt-to-equity ratio of 0.36.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IPA. Benchmark dropped their price objective on shares of ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating on the stock in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of ImmunoPrecise Antibodies in a report on Tuesday, July 30th.

View Our Latest Research Report on ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Company Profile

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.